TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30690595
Drug: Lung lavage
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung lavage with diluted porcine surfactant (30 ml/kg)
Study: 30690595
Drug: Bolus surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus surfactant (100 mg/kg)
Study: 24755958
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg/d) in combination with docetaxel (75 mg/m2)
Study: 10474062
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of DUP 996
Study: 10474062
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of DUP 996
Study: 10474062
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of DUP 996
Study: 28325960
Drug: Paracetamol-Codeine (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-Codeine (analgesic group)
Study: 26747845
Drug: W +
Normalized name: Culturelle Baby Grow + Thrive
Approvals — FDA: no, EMA: no, PMDA: no
Description: W + 2 day live TF‐CBT workshop + twice monthly phone consultation (W + L)
Study: 22971521
Drug: 6 repeat
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 repeat intradermal injections of grass pollen extract (7 ng of Phl p 5 per injection) at 2-week intervals
Study: 22971521
Drug: 2 intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 intradermal injections separated by 10 weeks
Study: 22971521
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intradermal injection at 10 weeks
Study: 19397752
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone (0.5 mg/kg)
Study: 15179544
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day, orally)
Study: 11251702
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous magnesium sulfate
Study: 11251702
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.9% saline (placebo)
Study: 11251702
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous magnesium sulfate (after placebo)
Study: 28655036
Drug: Simultaneous BiCIs
Normalized name: bicisate
DrugBank: Bicisate (DB11164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous BiCIs (2 cochlear implants during 1 surgical procedure)
Study: 28655036
Drug: Sequential BiCIs
Normalized name: bicisate
DrugBank: Bicisate (DB11164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential BiCIs (2 cochlear implants with an interval of 2 years between implants)
Study: 23989945
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment (home and GP)
Study: 23989945
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment locations
Study: 21928195
Drug: Thrombin bolus
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin bolus injection
Study: 21928195
Drug: Thrombin slow
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin slow injection
Study: 3552845
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg x 2)
Study: 3552845
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg x 2)
Study: 29809161
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel plus good wound care (BGWC)
Study: 29809161
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel plus good wound care (control)
Study: 24423298
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of pegvisomant
Study: 23539702
Drug: Active intense
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intense pulsed light (IPL) treatment
Study: 23539702
Drug: Placebo IPL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IPL treatment
Study: 17764767
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) group (10^8 cells)
Study: 17764767
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) group (10^7 cells)
Study: 12552359
Drug: Modafinil 300
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300 mg
Study: 12552359
Drug: d-Amphetamine 20
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine 20 mg
Study: 10986991
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special treatment
Study: 27296693
Drug: rTSST-1v (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTSST-1v (100 ng to 30 μg)
Study: 27296693
Drug: Al(OH)3 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al(OH)3 (200 μg, 600 μg, or 1 mg)
Study: 20395895
Drug: 0 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mL saline
Study: 20395895
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL saline
Study: 20395895
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL saline
Study: 20395895
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL saline
Study: 18304239
Drug: Tooth Mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth Mousse containing CPP-ACP as a topical coating - Group D
Study: 18304239
Drug: Tooth Mousse
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth Mousse containing CPP-ACP as a topical coating after fluoridated toothpaste - Group E
Study: 16253978
Drug: OC-scheduled GnRH
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-scheduled GnRH antagonist (ganirelix)
Study: 16253978
Drug: Non-scheduled GnRH
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-scheduled GnRH antagonist
Study: 12108857
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg, twice daily via Turbuhaler
Study: 1967210
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug plus weight loss groups
Study: 366719
Drug: Aspirin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (5 grain ASA capsules)
Study: 25823275
Drug: Umifenovir 200
Normalized name: umifenovir
DrugBank: Umifenovir (DB13609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umifenovir 200 mg four times daily for 5 days
Study: 24055306
Drug: Fluzone(®) Intradermal
Normalized name: Fluzone 2018-2019
DrugBank: Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) (DB14454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone(®) Intradermal vaccine
Study: 24055306
Drug: Fluzone(®) Intramuscular
Normalized name: Fluzone 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzone(®) Intramuscular vaccine
Study: 21865396
Drug: H5N1 VLP
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 VLP vaccine at 15, 45, or 90 μg HA/dose
Study: 1644089
Drug: Captopril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (up to 150 mg/day for 6 weeks)
Study: 6084121
Drug: Guanabenz 16
Normalized name: guanabenz 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz 16 mg
Study: 6084121
Drug: Guanabenz (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (2 to 32 mg)
Study: 6084121
Drug: Guanabenz 16
Normalized name: guanabenz 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz 16 mg (sublingual and oral)
Study: 31555926
Drug: 10-day normobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day normobaric hypoxic confinement (FiO2=0.14) with daily 90-min normoxic controlled hyperthermia (target rectal temperature: 38.5 °C)
Study: 29969301
Drug: L-ornithine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine (400 mg)
Study: 23149929
Drug: Mirabegron 200
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 200 mg
Study: 20336066
Drug: Aleglitazar (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar (doses >300 microg)
Study: 15826316
Drug: 5-Fluorouracil; Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation, followed by continuous 5-FU infusions for two more cycles.
Study: 15826316
Drug: 5-FU with
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU with intravenous bolus injections of folinic acid on 5 consecutive days every 28 days for 6 cycles.
Study: 1963274
Drug: Pirarubicin 20
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin 20 mg/m2
Study: 1963274
Drug: Pirarubicin 24
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin 24 mg/m2
Study: 1963274
Drug: Pirarubicin 25
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin 25 mg/m2
Study: 1963274
Drug: Pirarubicin 27
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin 27 mg/m2
Study: 1963274
Drug: Pirarubicin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (all doses)
Study: 24495883
Drug: Intracoronary melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary melatonin administration
Study: 23277643
Drug: Oridermyl (acaricidal/antibiotic/
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oridermyl (acaricidal/antibiotic/ antifungal/anti‐inflammatory ointment), treated once daily for 10 days
Study: 21049628
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: Tpanax Notoginseng Pills PO, Lornoxicam For Injection, 8 mg IM
Study: 21049628
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: Tpanax Notoginseng Pills PO, Tong Mai Decoctions 200 mL PO
Study: 21049628
Drug: Group IV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV: Tpanax Notoginseng Pills PO, Lornoxicam For Injection 8 mg IM, Tong Mai Decoctions 200 mL PO
Study: 21049628
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Tpanax Notoginseng Pills PO
Study: 16945983
Drug: Multi-component educational
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component educational intervention delivered by health personnel as part of usual care; details on dosage and duration not specified.
Study: 16945983
Drug: Existing nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing nutrition education (control group); details on dosage and duration not specified.
Study: 17877120
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg/day, 25 mg/day, 50 mg/day) administered in increasing doses every four weeks
Study: 10522506
Drug: Oxymetazoline hydrochloride
Normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline hydrochloride (0.5 mg/mL) nasal spray containing benzalkonium chloride (0.1 mg/mL)
Study: 1971461
Drug: Benzyl-1 isoquinoline
Normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzyl-1 isoquinoline derivative (458 L)
Study: 7027062
Drug: 1 alpha-hydroxycholecalciferol
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha-hydroxycholecalciferol (2 micrograms daily for 3 months, then 1 microgram daily for 9 months)
Study: 21270743
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) as preexposure prophylaxis (PrEP)
Study: 19246334
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/d (RSV10 group)
Study: 19246334
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/d (RSV20 group)
Study: 17454156
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily from cycle day 3 to day 7
Study: 17454156
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg daily from cycle day 3 to day 7
Study: 15114429
Drug: 75 micro
Normalized name: Norgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 micro g midazolam
Study: 15114429
Drug: ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole (200 mg b.i.d.)
Study: 15114429
Drug: rifampicin (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampicin (450 mg q.d.)
Study: 11826546
Drug: Fosinopril 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 10, 20, and 40 mg as monotherapy
Study: 8034781
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel + SCRP
Study: 2539025
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus dihydroergotamine mesylate (5,000 IU unfractionated heparin plus 0.5 mg dihydroergotamine mesylate twice daily)
Study: 2539025
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin plus dihydroergotamine mesylate (1,500 IU low-molecular weight heparin plus 0.5 mg dihydroergotamine mesylate once daily)
Study: 2539025
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin plus dihydroergotamine mesylate
Study: 2539025
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus dihydroergotamine mesylate
Study: 29330978
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection for sensory blockade
Study: 23735819
Drug: Epoetin-alfa (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alfa (average weekly doses ranging from 133 to 19,106 units/week)
Study: 23735819
Drug: Epoetin-alfa (middle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alfa (middle tertile of Hb achieved >11.5 to <12.7 g/dl and lowest tertile of epoetin-alfa dose exposure level <5,164 units/week)
Study: 23735819
Drug: Epoetin-alfa (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alfa (average weekly dose)
Study: 16422971
Drug: Vardenafil 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10/20 mg
Study: 29864043
Drug: Electrical dry
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical dry needling, manual therapy (MT), and exercise
Study: 29864043
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) and exercise
Study: 26186644
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of pitavastatin calcium
Study: 26186644
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of pitavastatin calcium
Study: 23878024
Drug: Modified grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified grapefruit juice (GFJ) (240 mL)
Study: 23878024
Drug: Original grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original grapefruit juice (GFJ) (240 mL)
Study: 20185386
Drug: Etanercept 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 0.8 mg/kg (<= 50 mg) once weekly for 12 weeks
Study: 18185506
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH) levels maintained in the target range of 150-300 pg ml(‐1)
Study: 18185506
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH) levels less than 150 pg ml(‐1)
Study: 18185506
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone (iPTH) levels greater than 300 pg ml(‐1)
Study: 10514345
Drug: Recombinant glucagon
Normalized name: Glucagon recombinant
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant glucagon (rG) pH 2.0 administered intramuscularly (im)
Study: 10514345
Drug: Recombinant glucagon
Normalized name: Glucagon recombinant
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant glucagon (rG) pH 2.0 administered subcutaneously (sc)
Study: 8949429
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 micrograms/g once daily)
Study: 8949429
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream twice daily
Study: 8949429
Drug: Calcipotriol and
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol and clobetasone 17-butyrate (0.5 mg/g) creams
Study: 8949429
Drug: Calcipotriol and
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol and betamethasone 17-valerate (1 mg/g) creams
Study: 8949429
Drug: Calcipotriol monotherapy
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol monotherapy (once daily)
Study: 28702809
Drug: Racemic formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic formoterol (2 × 27 µg)
Study: 24963111
Drug: Salsalate (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3.5 g daily for 4 weeks)
Study: 22704274
Drug: GPs' treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPs' treatment effect
Study: 22267373
Drug: Letrozole 5
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5 mg daily for 5 days
Study: 19089782
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for 5 days
Study: 17879495
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs with oral prednisolone (1 mg/kg body weight for 7 days, tapering off over 3 days)
Study: 17879495
Drug: Antiepileptic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic monotherapy
Study: 15080019
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg IV and 16 mg in PCA pump)
Study: 12479110
Drug: Tramadol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Study: 12479110
Drug: Morphine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Study: 12479110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tramadol (6 mg/kg), morphine (0.12 mg/kg), and 0.125% bupivacaine (100 ml) for 48 hours
Study: 3674580
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 800 micrograms per day
Study: 3674580
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) changed to oral theophylline
Study: 24955452
Drug: Monthly endoscopic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly endoscopic variceal ligation (EVL)
Study: 23341517
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) with concurrent cisplatin 100 mg/m(2) on days 1, 22, and 43 of RT (arm A)
Study: 23341517
Drug: Bioradiotherapy (BRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioradiotherapy (BRT) with concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B)
Study: 18822428
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose 0.75 microg/kg/min for 3 hours then maintenance 0.2 microg/kg/min until 18 hours after birth)
Study: 8995087
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of aspirin or anticoagulant therapy
Study: 8995087
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents and captopril
Study: 30763405
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment before immunisation
Study: 30763405
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment at immunisation
Study: 29547049
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (de novo group)
Study: 29547049
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (prior octreotide group)
Study: 24338935
Drug: Spironolactone (titrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (titrating dose, 12.5-50 mg once daily)
Study: 24338935
Drug: Clonidine (titrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (titrating dose, 0.1-0.3 mg twice daily)